TR200301614A2 - Atorvastatin kalsiyum tablet formülasyonunun hazırlanması için yeni yöntem - Google Patents

Atorvastatin kalsiyum tablet formülasyonunun hazırlanması için yeni yöntem

Info

Publication number
TR200301614A2
TR200301614A2 TR2003/01614A TR200301614A TR200301614A2 TR 200301614 A2 TR200301614 A2 TR 200301614A2 TR 2003/01614 A TR2003/01614 A TR 2003/01614A TR 200301614 A TR200301614 A TR 200301614A TR 200301614 A2 TR200301614 A2 TR 200301614A2
Authority
TR
Turkey
Prior art keywords
preparation
new method
tablet formulation
atorvastatin calcium
calcium tablet
Prior art date
Application number
TR2003/01614A
Other languages
English (en)
Inventor
Seyed Farshi Farhad
Original Assignee
Bi̇ofarma İlaç Sanayi̇ Ve Ti̇caret A.Ş.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bi̇ofarma İlaç Sanayi̇ Ve Ti̇caret A.Ş. filed Critical Bi̇ofarma İlaç Sanayi̇ Ve Ti̇caret A.Ş.
Priority to TR2003/01614A priority Critical patent/TR200301614A2/tr
Priority to PCT/TR2004/000042 priority patent/WO2005030183A2/en
Publication of TR200301614A2 publication Critical patent/TR200301614A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Mevcut buluş; Atorvastatin kalsiyum filmtablet hazırlanmasında formülasyonda kullanılan yardımcı maddelerin olumsuz etkilerini ortadan kaldırmak amacıyla geliştirilmiştir.
TR2003/01614A 2003-09-26 2003-09-26 Atorvastatin kalsiyum tablet formülasyonunun hazırlanması için yeni yöntem TR200301614A2 (tr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TR2003/01614A TR200301614A2 (tr) 2003-09-26 2003-09-26 Atorvastatin kalsiyum tablet formülasyonunun hazırlanması için yeni yöntem
PCT/TR2004/000042 WO2005030183A2 (en) 2003-09-26 2004-09-24 A method for the preparation of atorvastatin calcium tablets

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2003/01614A TR200301614A2 (tr) 2003-09-26 2003-09-26 Atorvastatin kalsiyum tablet formülasyonunun hazırlanması için yeni yöntem

Publications (1)

Publication Number Publication Date
TR200301614A2 true TR200301614A2 (tr) 2005-10-21

Family

ID=34388831

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2003/01614A TR200301614A2 (tr) 2003-09-26 2003-09-26 Atorvastatin kalsiyum tablet formülasyonunun hazırlanması için yeni yöntem

Country Status (2)

Country Link
TR (1) TR200301614A2 (tr)
WO (1) WO2005030183A2 (tr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2070520A1 (en) 2007-12-11 2009-06-17 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising at least one active agent and a binder, which swells in an acidic media
KR101950907B1 (ko) * 2016-02-05 2019-02-21 한국유나이티드제약 주식회사 지용성 약물 및 방유성 기제가 코팅된 고형제제를 포함하는 경구용 복합제제
CN106420645A (zh) * 2016-11-24 2017-02-22 浙江新东港药业股份有限公司 一种含阿托伐他汀钙片及制备方法
CN108421045B (zh) * 2018-04-02 2021-09-24 北京海晶生物医药科技有限公司 一种阿托伐他汀钙组合物、制剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016693A1 (en) * 1993-01-19 1994-08-04 Warner-Lambert Company Stable oral ci-981 formulation and process of preparing same
JP3397385B2 (ja) * 1993-09-20 2003-04-14 第一製薬株式会社 崩壊遅延防止錠剤
US6649186B1 (en) * 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij

Also Published As

Publication number Publication date
WO2005030183A3 (en) 2005-09-09
WO2005030183A2 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
UA115131C2 (uk) Сполуки боронатного ефіру і його фармацевтичні рецептури
UY28215A1 (es) Quinazolinas utiles como moduladores de canales iónicos
HN2003000054A (es) Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo (cetpi), a procedimientos de uso y a procedimientos de preparacion de las mismas.
EA201070247A1 (ru) Ингибиторы протеасом
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
SE0301700D0 (sv) Novel compounds
EA200601253A1 (ru) Преимущественно линейная шипучая лекарственная форма фентанила для перорального применения и способы введения
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
TW200616661A (en) HER2 antibody composition
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
RS51213B (sr) Farmaceutski vaginalni gel koji sadrži tenofovir
CL2009000967A1 (es) Compuesto 4-ciclobutil-n-((2s,5r)-5-hidroxi-2-adamantil)-2-morfolin-4-ilpiridin-5-carboxamida, inhibidor de la enzima 11betahsd1; composicion farmaceutica que lo comprende; y su uso en un procedimiento de tratamiento profilactico o terapeutico de un animal de sangre caliente.
CY1109962T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-ονης για τη θεραπεια παχυσαρκιας
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
DE60334773D1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
CL2004000647A1 (es) Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am
RS51271B (sr) Čvrsta farmaceutska kompozicija koja sadrži donepezil hidrohlorid
NO20071604L (no) Loxapinanaloger og fremgangsmater for anvendelse derav.
CY1113462T1 (el) Μορφη δοσολογιας περιεχουσα παντοπραζολη ως δραστικο συστατικο
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
UY31403A1 (es) "derivados novedosos de ({((3-metilfenil)-2h-tetrazol-5-il)-etoxi} -4h-1,2,4-triazol-3-il), composiciones farmacéuticas conteniendolos y uso médico de los mismos".
HRP20041013B1 (hr) Formulacija visoke doze ibandronata
TR200301614A2 (tr) Atorvastatin kalsiyum tablet formülasyonunun hazırlanması için yeni yöntem
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение